Method of inhibiting dopaminergic cell death

Abstract

Soluble Neuregulin-1 isoforms representing Posttranslational Neuregulin-1 modifications for reducing dopaminergic cell death.

1 . A method of reducing dopaminergic cell death in a subject in need thereof, comprising administering to said subject an effective amount of recombinant soluble Type I Neuregulin-1 β isoform which is an about 15 to about 35 kD N-terminal fragment of Type I Neuregulin-1 β. 
     
     
         2 . The method of  claim 1 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 150 to 250 amino acids of Type I Neuregulin-1 β. 
     
     
         3 . The method of  claim 1 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 245 to 250 amino acids of Type I Neuregulin-1 β. 
     
     
         4 . The method of  claim 1 , wherein the Type I Neuregulin-1 β isoform has an isoelectric point (pI) of about 4 to about 10. 
     
     
         5 . The method of  claim 1 , wherein the Type 1 Neuregulin-1 β isoform is a modified polypeptide, wherein the modifications are selected from phosphorylation, glycosylation, methylation, myristoylation, oxidation and any combination thereof. 
     
     
         6 . A method of promoting neuroprotection comprising administering a recombinant soluble Type I Neuregulin-1 β isoform which is an about 15 to about 35 kD N-terminal fragment of Type I Neuregulin-1 β to a subject in need thereof. 
     
     
         7 . The method of  claim 6 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 150 to 250 amino acids of Type I Neuregulin-1 β. 
     
     
         8 . The method of  claim 6 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 245 to 250 amino acids of Type I Neuregulin-1 β. 
     
     
         9 . The method of  claim 6 , wherein the Type I Neuregulin-1 β isoform has an isoelectric point (pI) of about 4 to about 10. 
     
     
         10 . The method of  claim 6 , wherein the Type I Neuregulin-1 β isoform is a modified polypeptide, wherein the modifications are selected from phosphorylation, glycosylation, methylation, myristoylation, oxidation and any combination thereof. 
     
     
         11 . A method of enhancing memory in a subject in need thereof comprising administering to said subject a recombinant soluble Type I Neuregulin-1 β isoform which is an about 15 to about 35 kD N-terminal fragment of Type I Neuregulin-1 β. 
     
     
         12 . The method of  claim 11 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 150 to 250 amino acids of Type I Neuregulin-1 β. 
     
     
         13 . The method of  claim 11 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 245 to 250 amino acids of Type I Neuregulin-1 β. 
     
     
         14 . The method of  claim 11 , wherein the Type I Neuregulin-1 β isoform has an isoelectric point (pI) of about 4 to about 10. 
     
     
         15 . The method of  claim 11 , wherein the Type I Neuregulin-1 β isoform is a modified polypeptide, wherein the modifications are selected from phosphorylation, glycosylation, methylation, myristoylation, oxidation and any combination thereof. 
     
     
         16 . A method of effecting antipsychotic activity in a subject in need thereof comprising administering to said subject a recombinant soluble Type I Neuregulin-1 β isoform which is an about 15 to about 35 kD N-terminal fragment of Type I Neuregulin-1 β. 
     
     
         17 . The method of  claim 16 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 150 to 250 amino acids of Type I Neuregulin-1 β. 
     
     
         18 . The method of  claim 16 , wherein said recombinant soluble Type I Neuregulin-1 β isoform is the first 245 to 250 amino acids of Type I Neuregulin-1 β. 
     
     
         19 . The method of  claim 16 , wherein the Type I Neuregulin-1 β isoform has an isoelectric point (pI) of about 4 to about 10. 
     
     
         20 . The method of  claim 16 , wherein the Type I Neuregulin-1 β isoform is a modified polypeptide, wherein the modifications are selected from phosphorylation, glycosylation, methylation, myristoylation, oxidation and any combination thereof.